## Pertuzumab Clinical Trial

NCT01959490 Case Comprehensive Cancer Center National Stage II Breast Cancer Stage IIIA Breast 24-Sep-13 Cancer Institute (NCI) Cancer Stage IIIB Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer  NCT00943670 Genentech, Inc. Metastatic Breast Cancer 9-Jul Phase 2  NCT04900311 Tianjin Medical University Cancer Institute and HER2&addition Early or Locally 21-May Phase 2  Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University  NCT02004093 Hoffmann-La Roche Ovarian Cancer 5-Dec Phase 2  NCT01684878 Hoffmann-La Roche Ovarian Cancer 22-Oct-12 Phase 3  NCT04411550 Shanghai Henlius Biotech Healthy Male Volunteers 20-Jul Phase 1  NCT04193059 Fudan University Breast Cancer 1-Aug-18 Phase 3  NCT03125928 Fox Chase Cancer Center Genentech, Inc. HER2-positive Breast Cancer 1-May-21 Phase 2  NCT01918254 Hoffmann-La Roche Breast Cancer 6-Aug-13 Phase 1  NCT04777531 The First Affiliated Hospital with Nanjing Breast Cancer 3-Jun-21 Phase 2
NCT04900311 Tianjin Medical University Cancer Institute and HER2&addition Early or Locally Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University  NCT02004093 Hoffmann-La Roche NCT01684878 Hoffmann-La Roche NCT04411550 Shanghai Henlius Biotech NCT04193059 Fudan University  Breast Cancer  Breast Cancer 1-Aug-18 Phase 3  NCT03125928 Fox Chase Cancer Center Genentech, Inc. NCT04680442 Population Health Research Institute Breast Cancer Breast Cancer Breast Cancer 6-Aug-13 Phase 1
Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University  NCT02004093 Hoffmann-La Roche Ovarian Cancer 5-Dec Phase 2  NCT01684878 Hoffmann-La Roche Ovarian Cancer 22-Oct-12 Phase 3  NCT04411550 Shanghai Henlius Biotech Healthy Male Volunteers 20-Jul Phase 1  NCT04193059 Fudan University Breast Cancer 1-Aug-18 Phase 3  NCT03125928 Fox Chase Cancer Center Genentech, Inc. HER2-positive Breast Cancer 13-Jun-17 Phase 2  NCT04680442 Population Health Research Institute Breast Cancer Heart Failure 1-May-21 Phase 2  NCT01918254 Hoffmann-La Roche Breast Cancer 6-Aug-13 Phase 1
Sun Yat-Sen UniversityNCT02004093Hoffmann-La RocheOvarian Cancer5-DecPhase 2NCT01684878Hoffmann-La RocheOvarian Cancer22-Oct-12Phase 3NCT04411550Shanghai Henlius BiotechHealthy Male Volunteers20-JulPhase 1NCT04193059Fudan UniversityBreast Cancer1-Aug-18Phase 3NCT03125928Fox Chase Cancer Center Genentech, Inc.HER2-positive Breast Cancer13-Jun-17Phase 2NCT04680442Population Health Research InstituteBreast Cancer Heart Failure1-May-21Phase 2NCT01918254Hoffmann-La RocheBreast Cancer6-Aug-13Phase 1
NCT01684878Hoffmann-La RocheOvarian Cancer22-Oct-12Phase 3NCT04411550Shanghai Henlius BiotechHealthy Male Volunteers20-JulPhase 1NCT04193059Fudan UniversityBreast Cancer1-Aug-18Phase 3NCT03125928Fox Chase Cancer Center Genentech, Inc.HER2-positive Breast Cancer13-Jun-17Phase 2NCT04680442Population Health Research InstituteBreast Cancer Heart Failure1-May-21Phase 2NCT01918254Hoffmann-La RocheBreast Cancer6-Aug-13Phase 1
NCT04411550Shanghai Henlius BiotechHealthy Male Volunteers20-JulPhase 1NCT04193059Fudan UniversityBreast Cancer1-Aug-18Phase 3NCT03125928Fox Chase Cancer Center Genentech, Inc.HER2-positive Breast Cancer13-Jun-17Phase 2NCT04680442Population Health Research InstituteBreast Cancer Heart Failure1-May-21Phase 2NCT01918254Hoffmann-La RocheBreast Cancer6-Aug-13Phase 1
NCT04193059Fudan UniversityBreast Cancer1-Aug-18Phase 3NCT03125928Fox Chase Cancer Center Genentech, Inc.HER2-positive Breast Cancer13-Jun-17Phase 2NCT04680442Population Health Research InstituteBreast Cancer Heart Failure1-May-21Phase 2NCT01918254Hoffmann-La RocheBreast Cancer6-Aug-13Phase 1
NCT03125928Fox Chase Cancer Center Genentech, Inc.HER2-positive Breast Cancer13-Jun-17Phase 2NCT04680442Population Health Research InstituteBreast Cancer Heart Failure1-May-21Phase 2NCT01918254Hoffmann-La RocheBreast Cancer6-Aug-13Phase 1
NCT04680442Population Health Research InstituteBreast Cancer Heart Failure1-May-21Phase 2NCT01918254Hoffmann-La RocheBreast Cancer6-Aug-13Phase 1
NCT01918254 Hoffmann-La Roche Breast Cancer 6-Aug-13 Phase 1
NCT0//717531 The First Affiliated Hospital with Naning Project Cancer 2 Jun 24 Phose 2
NCT04717531 The First Affiliated Hospital with Nanjing Breast Cancer 3-Jun-21 Phase 2
Medical University
NCT04341181 Ulrik Lassen Roche Pharma Cancer Tumors Neoplasms Neoplasia 24-Aug-20 Phase 2
AG Pfizer GlaxoSmithKline Rigshospitalet,
Denmark
NCT03144947 Gruppo Oncologico Italiano di Ricerca Cancer, Breast 29-Nov-16 Phase 2
Clinica University Hospital of Parma:
Department of Biomedical, Biotechnological
and Translational Sciences, Pathological
Anatomy and Histology Unit University  Hospital of Parma:Laboratory of Viral
Immunopathology, Unit of Infectious Diseases
and Hepatology University Hospital of
Parma:Statistica medica ed epidemiologia
clinica-UO Ricerca e Innovazione Clirest
s.r.l. Mipharm SpA Arithmos srl Temas srl
NCT02507375 Hoffmann-La Roche Non-Small Cell Lung Cancer 6-Sep Phase 1
NCT01501487 Agendia University of South Florida University Breast Cancer 11-Oct Phase 4
of Miami Morton Plant Mease Health
Care AdventHealth Plano Cancer Center Ohio
State University Comprehensive Cancer
Center University of Oklahoma University of
South Alabama

NCT01048099	SCRI Development Innovations, LLC Prometheus Laboratories Genentech, Inc.	Breast Cancer	11-Jan	Not Applicable
NCT01597414	European Organisation for Research and Treatment of Cancer - EORTC Hoffmann-La Roche	Elderly Metastatic Breast Cancer Population	13-Jun	Phase 2
NCT00567190	Genentech, Inc. Hoffmann-La Roche	Metastatic Breast Cancer	12-Feb-08	Phase 3
NCT04425018	Dana-Farber Cancer	Breast Cancer Stage II Breast	13-Jul-20	Phase 2
	Institute MacroGenics Translational Breast	Cancer Stage III Breast		
	Cancer Research Consortium	Cancer HER2-positive Breast Cancer		
NCT02625441	Helsinki University Central Hospital	Breast Cancer	15-Dec	Phase 3
NCT02336984	H. Lee Moffitt Cancer Center and Research Institute	Breast Cancer	14-Jun	Phase 1 Phase 2
NCT02131064	Hoffmann-La Roche	Breast Neoplasms	25-Jun-14	Phase 3
NCT03238495	Qamar Khan University of Kansas Medical	HER2-positive Breast Cancer	2-Aug-17	Phase 2
	Center			
NCT03894007	Renske Altena Karolinska University Hospital	Early-stage Breast	23-May-19	Phase 2
		Cancer HER2-positive Breast Cancer		
NCT03742986	NYU Langone Health	Breast Cancer	2-May-19	Phase 2
NCT03101748	M.D. Anderson Cancer Center National	Breast Inflammatory Carcinoma Locally	29-Jan-18	Phase 1 Phase 2
	Cancer Institute (NCI)	Advanced Breast Carcinoma Metastatic		
		Breast Carcinoma Stage III Breast		
		Cancer AJCC v7 Stage IIIA Breast		
		Cancer AJCC v7 Stage IIIB Breast		
		Cancer AJCC v7 Stage IIIC Breast		
		Cancer AJCC v7 Stage IV Breast Cancer	r	
		AJCC v6 and v7		
NCT04820439	The Affiliated Hospital of Qingdao University	Healthy Volunteers	13-Oct-20	Phase 1
NCT03716180	Dana-Farber Cancer Institute Susan G.	Breast Cancer	5-Nov-18	Phase 1
	Komen Breast Cancer Foundation Breast			
	Cancer Research Foundation Terri Brodeur			
	Breast Cancer Foundation			

Leukemia, BCR-ABL1 Positive|Anatomic

Stage IV Breast Cancer AJCC

v8|Anemia|Ann Arbor Stage III Hodgkin

Lymphoma|Ann Arbor Stage III

Non-Hodgkin Lymphoma|Ann Arbor

Stage IIIA Hodgkin Lymphoma|Ann Arbor

Stage IIIB Hodgkin Lymphoma|Ann Arbor

Stage IV Hodgkin Lymphoma|Ann Arbor

Stage IV Non-Hodgkin LymphomalAnn

Arbor Stage IVA Hodgkin

Lymphoma|Ann Arbor Stage IVB

Hodgkin Lymphoma|Atypical Chronic

Myeloid Leukemia, BCR-ABL1

Negative|Blast Phase Chronic

Myelogenous Leukemia, BCR-ABL1

Positive|Castration-Resistant Prostate

Carcinoma|Chronic Phase Chronic

Myelogenous Leukemia, BCR-ABL1

Positive|Hematopoietic and Lymphoid

Cell Neoplasm|Locally Advanced

Pancreatic Adenocarcinoma|Metastatic

Breast Carcinoma|Metastatic Malignant

Solid Neoplasm|Metastatic Pancreatic

Adenocarcinoma|Myelodysplastic+Myelo

proliferative Neoplasm With Ring

Sideroblasts and

Thrombocytosis|Myelodysplastic+Myelop

roliferative Neoplasm,

Unclassifiable|Primary

Myelofibrosis|Prognostic Stage IV Breast

Cancer AJCC v8|Recurrent Acute

Lymphoblastic Leukemia|Recurrent

Acute Myeloid Leukemia|Recurrent

Chronic Lymphocytic

Leukemia|Recurrent Chronic

Myelogenous Leukemia, BCR-ABL1

Positive|Recurrent Hematologic

Malignancy|Recurrent Hodgkin

Lymphoma|Recurrent Myelodysplastic

Syndrome|Recurrent

Myelodysplastic+Myeloproliferative

Neoplasm|Recurrent Myeloproliferative

Neoplasm|Recurrent Non-Hodgkin

Lymphoma|Recurrent Plasma Cell

Myeloma|Recurrent Small Lymphocytic

Lymphoma Refractory Acute
Lymphoblastic Leukemia Refractory
Acute Myeloid Leukemia Refractory
Chronic Lymphocytic
Leukemia Refractory Chronic
Myelogenous Leukemia, BCR-ABL1
Positive Refractory Chronic
Myelomonocytic Leukemia Refractory
Hematologic Malignancy Refractory
Hodgkin Lymphoma Refractory
Malignant Solid Neoplasm Refractory
Myelodysplastic Syndrome Refractory
Myelodysplastic+Myeloproliferative
Neoplasm Refractory Non-Hodgkin
Lymphoma Refractory Plasma Cell
Myeloma Refractory Primary
Myelofibrosis Refractory Small
Lymphocytic Lymphoma Stage II
Pancreatic Cancer AJCC v8 Stage IIA
Pancreatic Cancer AJCC v8 Stage IIB
Pancreatic Cancer AJCC v8 Stage III
Pancreatic Cancer AJCC v8 Stage IV
Pancreatic Cancer AJCC v8 Stage IV
Prostate Cancer AJCC v8 Stage IVA

Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Unresectable

Pancreatic Adenocarcinoma

NCT02229149	US Oncology Research Genentech, Inc.	Breast Neoplasms Malignant Tumor of	14-Dec	Phase 2
		the Breast		
NCT04024462	Hoffmann-La Roche	HER2-positive Early Breast Cancer	5-Feb-20	Phase 3
NCT01572038	Hoffmann-La Roche	Breast Neoplasms	1-Jun-12	Phase 3
NCT02060253	Memorial Sloan Kettering Cancer	HER2-positive Breast Cancer Male	April 2014	Phase 1
	Center National Cancer Institute (NCI) Synta	Breast Cancer Recurrent Breast		
	Pharmaceuticals Corp. New York University	Cancer Stage IIIA Breast Cancer Stage		
	Cancer Institute	IIIB Breast Cancer Stage IIIC Breast		
		Cancer Stage IV Breast Cancer		
NCT00951665	Genentech, Inc.	Metastatic Breast Cancer	9-Aug	Phase 1 Phase 2
NCT00551421	National Cancer Institute (NCI)	Adenocarcinoma of the	7-Oct	Phase 1 Phase 2
		Colon Adenocarcinoma of the		
		Rectum Recurrent Colon		
		Cancer Recurrent Rectal Cancer Stage		
		III Colon Cancer Stage III Rectal		
		Cancer Stage IV Colon Cancer Stage IV		
		Rectal Cancer		

NCT04108858	National Cancer Institute (NCI)	Anatomic Stage IV Breast Cancer AJCC v8 HER2-Positive Breast	6-Dec-19	Phase 1 Phase 2
		Carcinoma Metastatic Breast Carcinoma		
NCT00058539	Genentech, Inc.	Prostate Cancer	April 2003	Phase 2
NCT02000596	Katherine Tkaczuk Genentech, Inc. University	Metastatic Breast Cancer	14-Jan	Phase 2
	of Maryland, Baltimore			
NCT02789657	William Sikov MD Women and Infants	Breast Cancer	16-Nov	Phase 2
	Hospital of Rhode Island Rhode Island			
	Hospital The Miriam Hospital Brown University	,		
NCT04760431	Second Affiliated Hospital, School of	HER2-positive Breast Cancer Brain	1-Oct-21	Phase 2
	Medicine, Zhejiang University Peking	Metastases		
	University International Hospital Sun Yat-sen			
	University Zhejiang University			
NCT02345772	Western Regional Medical Center	HER2-positive Breast	14-Jul	Phase 1 Phase 2
		Cancer ER-positive Breast Cancer		
NCT00096993	Genentech, Inc.	Ovarian Cancer Peritoneal	5-Jan	Phase 2
		Cancer Fallopian Tube Cancer		
NCT01026142	Hoffmann-La Roche	Breast Cancer	26-Jan-10	Phase 3
NCT02605915	Hoffmann-La Roche	HER2-Positive Metastatic Breast	31-Dec-15	Phase 1
		Cancer HER2-Negative Metastatic		
		Breast Cancer Locally Advanced or Early		
		Breast Cancer		
NCT03304080	Icahn School of Medicine at Mount	Breast Neoplasms Breast Diseases	20-Dec-17	Phase 1 Phase 2
	Sinai Herbert Irving Comprehensive Cancer			
	Center Weill Medical College of Cornell			
	University NYU Langone Health			
NCT02125344	German Breast Group Amgen Roche Pharma	Tubular Breast Cancer Stage II Tubular	14-Dec	Phase 3
	AG Teva Pharmaceuticals USA Vifor Pharma	Breast Cancer Stage III Mucinous Breast		
		Cancer Stage II Breast Cancer Female		
		NOS Invasive Ductal Breast		
		Cancer HER2 Positive Breast		
		Cancer Inflammatory Breast Cancer		
NCT02326974	Dana-Farber Cancer Institute Genentech, Inc.	·	15-Jan	Phase 2
		Cancer Stage II Breast Cancer Stage III		
		Breast Cancer		
NCT03058939	University of Chicago	Breast Cancer Breast Cancer Stage	18-Nov	Phase 2
		II Breast Cancer Stage III		
NCT00833963	Genentech, Inc.	Breast Cancer Pregnancy	14-Jan-09	
NCT04629846	Qilu Pharmaceutical Co., Ltd.	Breast Cancer	20-Nov	Phase 3
NCT02390427	Dana-Farber Cancer Institute Genentech, Inc.	·	April 2015	Phase 1
		Breast Cancer		
NCT00934856	Hoffmann-La Roche	Breast Cancer	9-Jul	Phase 1 Phase 2
NCT01108458	George Albert Fisher Genentech,	Pancreatic Cancer	10-Jul	Phase 2
	Inc. Stanford University			
NCT04733118	MedSIR Hoffmann-La Roche	Early Breast Cancer	April 2021	Phase 2

NCT03498521	Hoffmann-La Roche Foundation Medicine,	Cancer of Unknown Primary Site	10-Jul-18	Phase 2
NCT03297606	Canadian Cancer Trials Group AstraZeneca Bristol-Myers Squibb Hoffmann-La Roche Pfizer	Lymphoma, Non-Hodgkin Multiple Myeloma Advanced Solid Tumors	6-Oct-17	Phase 2
NCT02445586	Hoffmann-La Roche	Breast Cancer	17-Aug-15	Phase 4
NCT01937117	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Translational Breast Cancer Research Consortium Genentech, Inc		30-Jan-14	Phase 2
NCT01817452	West German Study Group Roche Pharma	Breast Cancer	14-Mar	Phase 2
NCT03329378	Icahn School of Medicine at Mount Sinai	Locally Advanced Breast Cancer	30-Jan-19	Phase 2
NCT04246502	Shandong Cancer Hospital and Institute	Metastatic Breast Cancer	20-Jan	Phase 2
NCT00855894	Genentech, Inc. Roche Pharma AG	Non-Small Cell Lung Cancer	9-Mar	Phase 2
NCT02586025	Hoffmann-La Roche	Breast Cancer	14-Mar-16	Phase 3
NCT00545688	Hoffmann-La Roche	Breast Cancer	26-Jun-06	Phase 2
NCT01966471	Hoffmann-La Roche	Breast Cancer	31-Jan-14	Phase 3
NCT02624973	Haukeland University Hospital Helse Vest Pfizer AstraZeneca	Breast Cancer	April 15, 2016	Phase 2
NCT03820141	The Methodist Hospital Research Institute AstraZeneca	Breast Cancer	3-Mar-20	Phase 2
NCT03644186	International Breast Cancer Study Group Pfizer Hoffmann-La Roche	Breast Cancer Estrogen Receptor Positive Tumor HER2-positive Breast Cancer	April 16, 2019	Phase 2
NCT01042379	QuantumLeap Healthcare Collaborative	Breast Neoplasms Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-Negative Breast Cancer HER2-positive Breast Cancer HER2-negative Breast Cancer Hormone Receptor Positive Tumor Hormone Receptor Negative Tumor Early-stage Breast Cancer Locally Advanced Breast Cancer		Phase 2
NCT03264547	Japan Breast Cancer Research Group Eisai Co., Ltd.	Breast Cancer	28-Aug-17	Phase 3
NCT02568839	Thomas Hatschek Karolinska University Hospital	Early-Stage Breast Carcinoma HER-2 Positive Breast Cancer	14-Nov	Phase 2 Phase 3
NCT03845270	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer Stage III HER2 Gene Mutation	17-May-19	Phase 2
NCT03674112	Hoffmann-La Roche	HER2-Positive Early Breast Cancer	19-Dec-18	Phase 2
NCT01912963	Dana-Farber Cancer Institute Eisai	HER2-positive Breast Cancer Metastatic	13-Sep	Phase 2
NCT03988036	Inc. Genentech, Inc.  West German Study Group Merck Sharp &  Dohme Corp. NanoString Technologies, Inc.	Breast Cancer Breast Cancer	18-Aug-20	Phase 2

NCT02896855	Hoffmann-La Roche	Breast Cancer	13-Sep-16	Phase 3
NCT02073487	The Methodist Hospital Research	Breast Cancer	13-Sep-16	Phase 2
NC102073407	Institute Celgene Corporation Novartis	Dieast Galicei	14-1 60	i ilase 2
NCT01796197	Dana-Farber Cancer Institute	Breast Cancer	13-Aug	Phase 2
NCT02402712	Hoffmann-La Roche	Breast Cancer	6-May-15	Phase 3
NCT04197687	Academic and Community Cancer Research	-	-	Phase 2
110104101001	United National Cancer Institute (NCI)	Cancer AJCC v6 and v7 Stage IIA Breas		T Hase Z
	omeditational carlos monate (1701)	Cancer AJCC v6 and v7 Stage IIB Breas		
		Cancer AJCC v6 and v7 Stage III Breast		
		Cancer AJCC v7 Stage IIIA Breast		
		Cancer AJCC v7 Stage IIIB Breast		
		Cancer AJCC v7 Stage IIIC Breast		
		Cancer AJCC v7		
NCT02738970	Hoffmann-La Roche	Early Breast Cancer	23-Jun-16	Phase 1
NCT04329065	University of Washington National Cancer	Anatomic Stage I Breast Cancer AJCC	1-Nov-21	Phase 2
	Institute (NCI) United States Department of	v8 Anatomic Stage IA Breast Cancer		
	Defense	AJCC v8 Anatomic Stage IB Breast		
		Cancer AJCC v8 Anatomic Stage II		
		Breast Cancer AJCC v8 Anatomic Stage		
		IIA Breast Cancer AJCC v8 Anatomic		
		Stage IIB Breast Cancer AJCC		
		v8 Anatomic Stage III Breast Cancer		
		AJCC v8 Anatomic Stage IIIA Breast		
		Cancer AJCC v8 Anatomic Stage IIIB		
		Breast Cancer AJCC v8 Anatomic Stage		
		IIIC Breast Cancer AJCC v8 Prognostic		
		Stage I Breast Cancer AJCC		
		v8 Prognostic Stage IA Breast Cancer		
		AJCC v8 Prognostic Stage IB Breast		
		Cancer AJCC v8 Prognostic Stage II		
		Breast Cancer AJCC v8 Prognostic		
		Stage IIA Breast Cancer AJCC		
		v8 Prognostic Stage IIB Breast Cancer		
		AJCC v8 Prognostic Stage III Breast		
		Cancer AJCC v8 Prognostic Stage IIIA		
		Breast Cancer AJCC v8 Prognostic		
		Stage IIIB Breast Cancer AJCC		
		v8 Prognostic Stage IIIC Breast Cancer AJCC v8		
NCT02205047	European Organisation for Research and	Malignant Neoplasm of	15-Sep	Phase 2
	Treatment of Cancer - EORTC	Stomach Malignant Neoplasm of		
		Cardio-esophageal Junction of		
		Stomach Epidermal Growth Factor		
		Receptor (EGFR) Protein		
		Overexpression		
NCT01120184	Hoffmann-La Roche Genentech, Inc.	Breast Cancer	31-Jul-10	Phase 3
	第	7 页 共 14 页		

NCT02514681	Japan Breast Cancer Research Group Chuga	i HER2-positive Locally Advanced or	1-Aug-15	Phase 3
	Pharmaceutical	Metastatic Breast Cancer		
NCT01774786	Hoffmann-La Roche	Gastric Cancer	10-Jun-13	Phase 3
NCT01835236	Swiss Group for Clinical Cancer Research	Metastatic Breast Cancer	3-Mar-13	Phase 2
NCT04208178	Novartis Pharmaceuticals Novartis	Advanced HER2&additionBreast Cancer	16-Jul-20	Phase 3
NCT04158258	Hoffmann-La Roche Latin American Cooperative Oncology Group	Breast Cancer	21-Feb-20	
NCT02436993	University of California, Irvine	Breast Carcinoma	April 2015	Phase 2
NCT00947167	Pamela L. Kunz Genentech, Inc. Stanford	Neuroendocrine Tumors Carcinoid	9-Mar	Phase 2
	University	Tumors Adrenal Gland		
		Tumors Neuroblastoma Pancreatic		
		Neuroendocrine Tumors Multiple		
		Endocrine Neoplasia		
NCT03412643	NSABP Foundation Inc Celcuity, LLC Genentech, Inc.	HER2-negative Breast Cancer	14-May-18	Phase 2
NCT04337658	Second Affiliated Hospital, School of	HER2-positive Breast Cancer	1-Jul-20	Phase 3
	Medicine, Zhejiang University			
NCT02682693	German Breast Group Amgen Celgene	Breast Cancer Female NOS Tubular	13-Feb-17	Phase 2
	Corporation	Breast Cancer Stage II Mucinous Breast		
		Cancer Stage II Invasive Ductal Breast		
		Cancer HER2 Positive Breast		
		Cancer Inflammatory Breast		
		Cancer Tubular Breast Cancer Stage III		
NCT01855828	Yale University Genentech, Inc.	Her2-Positive Breast Cancer	13-Sep	Phase 2
NCT04578106	Fundacio Clinic Barcelona SOLTI Breast	HER2-positive Breast Cancer Stage I	23-Sep-20	Phase 2
	Cancer Research Group Roche Pharma AG	Breast Cancer		
NCT03135171	University of Michigan Rogel Cancer Center	Breast Cancer	26-Jul-17	Phase 1
NCT01875666	UNC Lineberger Comprehensive Cancer	Breast Neoplasms	5-Aug-13	Early Phase 1
	Center Genentech, Inc. Susan G. Komen			
	Breast Cancer Foundation GlaxoSmithKline			
NCT02019277	Hoffmann-La Roche	Breast Cancer	5-Dec-13	Phase 3
NCT04784715	AstraZeneca Daiichi Sankyo, Inc.	Breast Cancer; HER2-positive;	April 26, 2021	Phase 3
		Metastatic		
NCT05041842	UNICANCER Seagen Inc. ARCAGY+	Metastatic Breast Cancer With a Isolated	30-Sep-21	Phase 2
	GINECO GROUP	Brain Progression		
NCT03417544	Nancy Lin, MD Genentech, Inc. Dana-Farber		21-Feb-18	Phase 2
	Cancer Institute	Cancer Central Nervous System		
		Metastases		
NCT02091141	Genentech, Inc.	Neoplasms Solid Tumors Biliary	April 14, 2014	Phase 2
		Cancer Salivary Cancer Bladder Cancer		
NCT01491737	Hoffmann-La Roche	Breast Cancer	17-Feb-12	Phase 2
NCT02480010	Hoffmann-La Roche	Prostate Cancer	3-Sep	Phase 2
NCT02909751	Vejle Hospital	Breast Cancer	14-Sep-16	Phase 2

NCT04266249	ECOG-ACRIN Cancer Research Group National Cancer Institute (NCI) Eastern Cooperative Oncology Group	Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Invasive Breast Carcinoma Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8	11-Feb-20	Phase 2
NCT02411344	Istituto Oncologico Veneto IRCCS Association for Translational Research in Oncology (AS.T.R.O.)	Endocrine Sensitive HER2&addition+HR&addition Breast Cancer	14-Feb	Phase 2
NCT04675827	Jules Bordet Institute Breast International Group Hoffmann-La Roche International Drug Development Institute Institut Curie	HER2-positive Breast Cancer ER-Negative Breast Cancer PR-Negative Breast Cancer Node-negative Breast Cancer	21-Jun	Phase 2
NCT03747120	Cedars-Sinai Medical Center Merck Sharp & Dohme Corp.	HER2-positive Breast Cancer Breast Cancer	25-Jan-19	Phase 2
NCT04551521	German Cancer Research Center	Metastatic or Locally Advanced Malignancies	1-Aug-21	Phase 2
NCT03006172	Genentech, Inc.	Breast Cancer Solid Tumor	13-Dec-16	Phase 1
NCT00875979	Hoffmann-La Roche Roche Pharma AG	Metastatic Breast Cancer	9-May	Phase 1 Phase 2
NCT03493854	Hoffmann-La Roche	Early Breast Cancer	14-Jun-18	Phase 3
NCT04993014	AC Camargo Cancer Center	Breast Neoplasms HER2-positive Breast Cancer Circulating Tumor Cell	1-Mar-21	Phase 2
NCT00096941	Genentech, Inc.	Solid Cancers	5-May	Phase 2
NCT02689921	Midwestern Regional Medical Center	Breast Neoplasms	April 2016	Phase 2
NCT02003209	National Cancer Institute (NCI) NRG Oncology	HER2-Positive Breast Carcinoma Hormone Receptor-Positive Breast Carcinoma Stage IB Breast Cancer AJCC v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7		Phase 3
NCT03161353	MedSIR	Breast Cancer	26-Jun-17	Phase 2
NCT01121939	SCRI Development Innovations, LLC Genentech, Inc.	Neuroendocrine Carcinoma	10-May	Phase 2
NCT04538742	AstraZeneca Daiichi Sankyo Company, Limited	Metastatic Breast Cancer	28-Dec-20	Phase 1 Phase 2
NCT03726879	Hoffmann-La Roche Chugai Pharmaceutical	Breast Cancer	11-Jan-19	Phase 3
NCT00976989	Hoffmann-La Roche	Breast Cancer	9-Nov	Phase 2

NCT02252887	Memorial Sloan Kettering Cancer	Metastatic HER2-Positive Breast Cancer	12-Jan-15	Phase 2
	Center Genentech, Inc. Hoffmann-La			
	Roche Hartford HealthCare			
NCT04301375	David Garcia Cinca Fundacion Clinic per a la	Mammary Cancer	15-Jun-20	Phase 2
	Recerca Biomédica Hospital Clinic of			
	Barcelona			
NCT02536339	Genentech, Inc.	Metastatic Breast Cancer	16-Dec-15	Phase 2
NCT04395508	Genentech, Inc.	HER2-positive Breast Cancer		
NCT02139358	H. Lee Moffitt Cancer Center and Research	Breast Cancer	5-Sep-14	Phase 1 Phase 2
	Institute Genentech, Inc.			
NCT05020860	Baylor Breast Care Center	Breast Cancer Breast Neoplasm Breast	15-Oct-21	Phase 2
		Cancer Female Breast Cancer		
		Invasive Breast Cancer Stage II Breast		
		Cancer Stage III Triple Negative Breast		
		Cancer Hormone Receptor-positive		
		Breast Cancer HER2-positive Breast		
		Cancer Triple Negative Breast		
		Neoplasms Estrogen Receptor-positive		
		Breast Cancer		
NCT02693535	American Society of Clinical	Lymphoma, Non-Hodgkin Multiple	14-Mar-16	Phase 2
	Oncology AstraZeneca Bayer Bristol-Myers	Myeloma Advanced Solid Tumors		
	Squibb Eli Lilly and Company Genentech,			
	Inc. Merck Sharp & Dohme			
	Corp. Pfizer Boehringer Ingelheim Seagen			
	Inc.			
NCT02266173	Hoffmann-La Roche	Breast Cancer	5-Feb-15	
NCT01565083	Hoffmann-La Roche	Breast Cancer	April 2012	Phase 2
NCT04253561	SOLTI Breast Cancer Research Group Roche	Metastatic Breast Cancer	25-Feb-20	Phase 1
	Pharma AG			

NCT02465060	National Cancer Institute (NCI)	Advanced Malignant Solid	12-Aug-15	Phase 2
		Neoplasm Bladder Carcinoma Breast		
		Carcinoma Cervical Carcinoma Colon		
		Carcinoma Colorectal		
		Carcinoma Endometrial		
		Carcinoma Esophageal		
		Carcinoma Gastric		
		Carcinoma Glioma Head and Neck		
		Carcinoma Kidney Carcinoma Liver and		
		Intrahepatic Bile Duct Carcinoma Lung		
		Carcinoma Lymphoma Malignant Uterine		
		Neoplasm Melanoma Ovarian		
		Carcinoma Pancreatic		
		Carcinoma Plasma Cell		
		Myeloma Prostate Carcinoma Rectal		
		Carcinoma Recurrent Bladder		
		Carcinoma Recurrent Breast		
		Carcinoma Recurrent Cervical		
		Carcinoma Recurrent Colon		
		Carcinoma Recurrent Colorectal		
		Carcinoma Recurrent Esophageal		
		Carcinoma Recurrent Gastric		
		Carcinoma Recurrent Glioma Recurrent		
		Head and Neck Carcinoma Recurrent		
		Liver Carcinoma Recurrent Lung		
		Carcinoma Recurrent		
		Lymphoma Recurrent Malignant Solid		
		Neoplasm Recurrent		
		Melanoma Recurrent Ovarian		
		Carcinoma Recurrent Pancreatic		
		Carcinoma Recurrent Plasma Cell		
		Myeloma Recurrent Prostate		
		Carcinoma Recurrent Rectal		
		Carcinoma Recurrent Skin		
		Carcinoma Recurrent Thyroid Gland		
		Carcinoma Recurrent Uterine Corpus		
		Cancer Refractory Lymphoma Refractory	,	
		Malignant Solid Neoplasm Refractory		
		Plasma Cell Myeloma Skin		
		Carcinoma Thyroid Gland		
		Carcinoma Uterine Corpus Cancer		
NCT03112590	H. Lee Moffitt Cancer Center and Research	Breast Cancer Breast Cancer,	23-Jun-17	Phase 1 Phase 2
	Institute Horizon Pharma Ireland, Ltd., Dublin	·		-
	Ireland	Female HER2-positive Breast Cancer		
NCT01922921	University of Washington National Cancer	HER2+Neu Positive Recurrent Breast	5-Feb-14	Phase 1 Phase 2
	Institute (NCI) Office of Cancer	Carcinoma Stage IV Breast Cancer		
	, ,,	11 页 共 14 页		

## Complementary and Alternative Medicine

NCT02593708	Michelle Melisko University of California, San Francisco	Solid Tumor	3-Nov-15	Phase 1
NCT02925234	The Netherlands Cancer Institute Amgen AstraZeneca Bayer Bristol-My ers Squibb Novartis Roche Pharma AG Merck Sharp & Dohme Corp. Boehringer Ingelheim Ipsen Eisai Inc. Pfizer Clovis Oncology, Inc. Eli Lilly and Company Janssen LP		16-Aug	Phase 2
NCT02344472	Prof. W. Janni Roche Pharma AG Novartis Pharmaceuticals Eisai GmbH Celgene Corporation University of Ulm	Metastatic Breast Cancer	15-Sep	Phase 3
NCT02057133	Eli Lilly and Company	Breast Neoplasms	10-Mar-14	Phase 1
NCT04588545	H. Lee Moffitt Cancer Center and Research	HER2-positive Breast	10-Dec-20	Phase 1 Phase 2
	Institute Genentech, Inc.	Cancer Leptomeningeal		
		Metastasis Leptomeningeal Disease		
NCT00058552	Genentech, Inc.	Ovarian Cancer	3-May	Phase 2
NCT00301899	National Institutes of Health Clinical Center	Breast Cancer	5-Dec	Phase 2
	(CC) National Cancer Institute (NCI)			
NCT03595592	Fondazione Michelangelo Hoffmann-La Roche	Invasive Breast Cancer	7-Sep-18	Phase 3
NCT05036005	Institut fuer Frauengesundheit Samsung Bioepis Co., Ltd.	Breast Cancer Breast Neoplasms Breast Cancer Female HER2-positive Breast Cancer	11-Jul-21	Phase 4
NCT02530424	Fondazione Michelangelo	Breast Neoplasms	15-May	Phase 2
NCT01276041	Memorial Sloan Kettering Cancer Center Genentech, Inc. University of Pennsylvania	Breast Cancer	5-Jan-11	Phase 2
NCT02339532	UNICANCER	Breast Cancer	15-Jan	Phase 2
NCT01730833	City of Hope Medical Center National Cancer Institute (NCI)	HER2-positive Breast Cancer Recurrent Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Breast Adenocarcinoma Inflammatory Breast Carcinoma	17-Jul-13	Phase 2
NCT01358877	Hoffmann-La Roche Genentech, Inc. Breast International Group	Breast Cancer	8-Nov-11	Phase 3
NCT01850628	NSABP Foundation Inc Breast Cancer Research Foundation Washington University School of Medicine	Breast Cancer	13-Jul	

NCT04591431	Fondazione per la Medicina Personalizzata	Breast Cancer Gastrointestinal	7-Oct-20	Phase 2
		Cancer Non Small Cell Lung		
		Cancer Other Cancer		
NCT00063154	Genentech, Inc.	Non-small Cell Lung Cancer	3-Jul	Phase 2
NCT02827877	City of Hope Medical Center National Cancer	HER2 Positive Breast Carcinoma Stage	15-Jul-16	Phase 2
	Institute (NCI)	IIIA Breast Cancer Stage IIIB Breast		
		Cancer Stage IIIC Breast Cancer		
NCT02598427	Kimberly Blackwell Duke University	HER2 Positive Untreated Metastatic	1-May-17	Phase 1
		Breast Cancer Asymptomatic or Low		
		Symptomatic Brain Metastasis in Breast		
		Cancer		
NCT03199885	National Cancer Institute (NCI) NRG	Breast Adenocarcinoma Metastatic	12-Mar-19	Phase 3
	Oncology	Breast Adenocarcinoma Recurrent		
		Breast Carcinoma Stage III Breast		
		Cancer AJCC v7 Stage IIIA Breast		
		Cancer AJCC v7 Stage IIIB Breast		
		Cancer AJCC v7 Stage IIIC Breast		
		Cancer AJCC v7 Stage IV Breast Cancer		
		AJCC v6 and v7 Unresectable Breast		
NOTO		Carcinoma	4.1.00	DI 0
NCT04419181	University of Rochester	HER2-positive Breast Cancer	1-Jun-22	Phase 2
NCT02320435	Hoffmann-La Roche	Solid Tumor	2-Feb-15	Phase 3
NCT01847001	Columbia University	Locally Advanced Malignant	12-Oct	Phase 2
		Neoplasm Breast Cancer		
NCT01674062	Hoffmann-La Roche	Breast Cancer	6-May	Phase 2
NCT02132949	Hoffmann-La Roche	Breast Cancer	14-Jul-14	Phase 2
NCT01904903	Medstar Health Research	HER2 Positive Breast Cancer Left	13-Oct	Phase 2
	Institute Genentech, Inc.	Ventricular Function Systolic Dysfunction		
NCT02491892	Hoffmann-La Roche	Breast Cancer	3-Feb	Phase 2
NCT02947685	Alliance Foundation Trials,	HER-2 Positive Breast Cancer Estrogen	21-Jun-17	Phase 3
	LLC. Pfizer German Breast	Receptor Positive Breast Cancer		
	Group Fondazione Michelangelo PrECOG,			
	LLC. Breast Cancer Trials, Australia and New			
	Zealand Syneos Health SOLTI Breast Cancer			
	Research Group UNICANCER			<b>.</b>
NCT04398914	Shanghai Jiao Tong University School of	Breast Cancer Invasive	30-May-20	Phase 2
	Medicine Jiangsu HengRui Medicine Co., Ltd.			
NCT04957212	Cinnagen	HER2-positive Breast Cancer	11-Aug-18	Phase 3
NCT04514419	Zhe Jiang Hisun Bioray Bio-pharmaceu tical	Breast Cancer	30-Jun-20	Phase 3
NOTOOTOLOGO	Co.Ltd	Name and Make 1	40.0-4.00	DI- C
NCT00781612	Genentech, Inc. Hoffmann-La Roche	Neoplasm Metastasis	16-Oct-08	Phase 2
NCT03272477	Palleos Healthcare GmbH Roche Pharma	Breast Neoplasms	5-Oct-17	Phase 2
	AG WSG WOMEN'S HEALTHCARE STUDY			
	GROUP Cankado Service GmbH		A 11.47 CC.17	DI C
NCT02291289	Hoffmann-La Roche	Colorectal Cancer	April 17, 2015	Phase 2

NCT01461057	Hoffmann-La Roche	Gastric Cancer	6-Dec-11	Phase 2
NCT02379585	Western Regional Medical Center	HER2-positive Breast Cancer	13-Jan	Phase 1 Phase 2
NCT03365882	Southwest Oncology Group National Cancer	Colon Adenocarcinoma ERBB2 Gene	9-Oct-17	Phase 2
	Institute (NCI)	Amplification Rectal		
		Adenocarcinoma Recurrent Colon		
		Carcinoma Recurrent Rectal		
		Carcinoma Stage III Colon Cancer AJC0	0	
		v7 Stage III Rectal Cancer AJCC		
		v7 Stage IIIA Colon Cancer AJCC		
		v7 Stage IIIA Rectal Cancer AJCC		
		v7 Stage IIIB Colon Cancer AJCC		
		v7 Stage IIIB Rectal Cancer AJCC		
		v7 Stage IIIC Colon Cancer AJCC		
		v7 Stage IIIC Rectal Cancer AJCC		
		v7 Stage IV Colon Cancer AJCC		
		v7 Stage IV Rectal Cancer AJCC		
		v7 Stage IVA Colon Cancer AJCC		
		v7 Stage IVA Rectal Cancer AJCC		
		v7 Stage IVB Colon Cancer AJCC		
		v7 Stage IVB Rectal Cancer AJCC v7		
NCT03811418	iOMEDICO AG Arbeitsgemeinschaft fur	Advanced Breast Cancer HER2-positive	e 19-Jan	Phase 3
	Internistische Onkologie Amgen	Breast Cancer		